POSACONAZOLE-DRLA posaconazole 100 mg modified release tablet blister pack

País: Austràlia

Idioma: anglès

Font: Department of Health (Therapeutic Goods Administration)

ingredients actius:

posaconazole, Quantity: 100 mg

Disponible des:

Dr Reddys Laboratories Australia Pty Ltd

formulario farmacéutico:

Tablet, modified release

Composición:

Excipient Ingredients: hyprolose; iron oxide red; purified talc; microcrystalline cellulose; macrogol 400; hypromellose acetate succinate; magnesium stearate; triacetin; croscarmellose sodium; silicon dioxide; titanium dioxide; hypromellose

Vía de administración:

Oral

Unidades en paquete:

24, 96

tipo de receta:

(S4) Prescription Only Medicine

indicaciones terapéuticas:

POSACONAZOLE-DRLA (posaconazole) is indicated for use in the treatment of the following invasive fungal infections in patients 13 years of age or older: ,? Invasive aspergillosis in patients intolerant of, or with disease that is refractory to, alternative therapy. ,? Fusariosis, zygomycosis, coccidioidomycosis, chromoblastomycosis, and mycetoma in patients intolerant of, or with disease that is refractory to, alternative therapy. ,POSACONAZOLE-DRLA is also indicated for the: ,? Prophylaxis of invasive fungal infections among patients 13 years of age and older, who are at high risk of developing these infections, such as patients with prolonged neutropenia or haematopoietic stem cell transplant (HSCT) recipients.

Resumen del producto:

Visual Identification: Brown, capsule-shaped, bevelled edge, film-coated tablet, debossed with '470' on one side and plain on the other side.; Container Type: Blister Pack; Container Material: Al/Al; Container Life Time: 24 Months; Container Temperature: Store below 30 degrees Celsius; Container Closure: Neither child resistant closure nor restricted flow insert

Estat d'Autorització:

Registered

Data d'autorització:

2020-07-24